Compact accelerator-based production of carrier-free 177Lu from 18 MeV $$D^+$$ D + on [176Yb] $$\hbox {Yb}_2\hbox {O}_3$$ Yb 2 O 3

Abstract Background Recent EMA and FDA approvals of Lu-DOTATATE and Lu-PSMA-617 have led to increased demand for radiotherapeutic $$^{177}$$ 177 Lu, due to its promising potential to treat castration-resistant neuroendocrine cancers. Conventional reactor production methods pose challenges related to...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Austin A. Morris, Tianhao Wei, Zhi Wang, Ying Xia, Meiyun Han, Yuanrong Lu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	SpringerOpen 2025-08-01
coleção:	EJNMMI Radiopharmacy and Chemistry
Assuntos:	Lutetium( $$^{177}$$ 177 Lu) production Ytterbium( $$^{176}$$ 176 Yb) target Linear accelerator Radiopharmaceutical Neuroendocrine cancer
Acesso em linha:	https://doi.org/10.1186/s41181-025-00358-3
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!